A single-arm, open-label, phase II trial of BXCL701, an oral innate immune activator, in combination with Keytruda (pembrolizumab) in patients with small cell neuroendocrine prostate cancer showed positive overall survival data. As of a data cutoff of Sept. 6, evaluable patients with SCNC showed a median OS of 13.6 months, and a 12-month survival rate of 56.5%.
FDA approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
